These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 19917020)

  • 21. Antimicrobial resistance in gram-positive bacteria.
    Rice LB
    Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical therapy for serious Gram-positive infections: making the right choice.
    Segreti J
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():5-10. PubMed ID: 19917021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in treatment of antimicrobial-resistant enterococcal infections.
    Xia L; Murray BE
    Curr Clin Top Infect Dis; 2000; 20():92-112. PubMed ID: 10943520
    [No Abstract]   [Full Text] [Related]  

  • 24. [Emergence of vancomycin-dependent enterococci following glycopeptide therapy: case report and review].
    Bert F; Leflon-Guibout V; Le Grand J; Bourdon N; Nicolas-Chanoine MH
    Pathol Biol (Paris); 2009 Feb; 57(1):56-60. PubMed ID: 18845404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections.
    Fisher L; North D
    Int J Antimicrob Agents; 2009 May; 33(5):493-4. PubMed ID: 19153034
    [No Abstract]   [Full Text] [Related]  

  • 27. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future gazing in the management of multiply drug-resistant Gram-positive infection.
    Wilcox MH
    J Infect; 2009 Sep; 59 Suppl 1():S75-80. PubMed ID: 19766892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Infective endocarditis due to high level aminoglycoside resistant Enterococcus faecalis and methicillin resistant coagulase-negative staphylococci presenting with rheumatic manifestations].
    Pişkin N; Akduman D; Aydemir H; Celebi G; Oztoprak N; Aktaş E
    Mikrobiyol Bul; 2008 Jul; 42(3):509-14. PubMed ID: 18822897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature.
    Zeana C; Kubin CJ; Della-Latta P; Hammer SM
    Clin Infect Dis; 2001 Aug; 33(4):477-82. PubMed ID: 11462183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].
    Kuwahara K; Hanaki H; Hiramatsu K
    Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):182-5. PubMed ID: 10088368
    [No Abstract]   [Full Text] [Related]  

  • 35. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: relationships with antibiotic use and cost drivers.
    Mauldin PD; Salgado CD; Durkalski VL; Bosso JA
    Ann Pharmacother; 2008 Mar; 42(3):317-26. PubMed ID: 18285560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation.
    Sakoulas G
    Clin Microbiol Infect; 2009 Dec; 15 Suppl 6():11-6. PubMed ID: 19917022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates.
    Socha AM; LaPlante KL; Rowley DC
    Bioorg Med Chem; 2006 Dec; 14(24):8446-54. PubMed ID: 16979896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical correlates of vancomycin-resistant enterococci/meticillin-resistant Staphylococcus aureus co-colonization and co-infection in Singapore.
    Kurup A; Wong YY; Tan KY; Low JG
    J Hosp Infect; 2008 Nov; 70(3):291-2. PubMed ID: 18804897
    [No Abstract]   [Full Text] [Related]  

  • 39. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.